

Biophysical Journal, Volume 120

Supplemental information

Biophysical properties of the isolated spike protein binding helix of human ACE2

Anirban Das, Vicky Vishvakarma, Arpan Dey, Simli Dey, Ankur Gupta, Mitradip Das, Krishna Kant Vishwakarma, Debsankar Saha Roy, Swati Yadav, Shubham Kesarwani, Ravindra Venkatramani, and Sudipta Maiti

1 Supplementary Information for

2
3

4 Biophysical Properties of the Isolated Spike Protein Binding Helix of Human
5 ACE2

6

7 Anirban Das^{#§}, Vicky Vishvakarma^{#§}, Arpan Dey[#], Simli Dey[#], Ankur Gupta[#], Mitradip Das[#],
8 Krishna Kant Vishwakarma[#], Debsankar Saha Roy[#], Swati Yadav[^], Shubham Kesarwani[§],
9 Ravindra Venkatramani[#], and Sudipta Maiti^{#*}

10 [#]Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha
11 Road, Colaba, Mumbai 400005, India

12 [^]National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bellary
13 Road, Bangalore 560065, Karnataka, India

14 [§]Centre for Cardiovascular Biology and Disease (CCBD), Institute of Stem Cell Science and
15 Regenerative Medicine (inStem), Gandhi Krishi Vigyan Kendra Campus, Bangalore 560065,
16 Karnataka, India

17 [§]Equal contributions

18 *Email: maiti@tifr.res.in

19

20

21

22

23

24 This PDF file includes:

25

26 Figures S1-S11


27 Tables S1-S4

28 Section S1: Theoretical calculations of the hydrodynamic radius and comparison with the
29 experimental results

30 Section S2: Computational methods

31 SI References


32



33

34 **Figure S1.** Matrix-assisted laser desorption/ionization - time-of-flight (MALDI-TOF) mass
35 spectrum (in reflector positive mode) of the N-terminal Fmoc-protected SBP1-CONH₂. The
36 peptide was dissolved in 1:1 acetonitrile-water mixture containing 0.1% trifluoroacetic acid
37 and used for the MS analysis.

38



39


40 **Figure S2.** MALDI-TOF mass spectrum (in reflector positive mode) of the N-terminal Cyanine
41 3-labelled SBP1-CONH₂ (Cy3-SBP1-CONH₂). The peak at m/z = 3369.58 (highest intensity peak)
42 corresponds to dye labelled SBP1 peptide. This indicates that the dye labelling was complete
43 (~100%).

44

45 **(A) Spectrum View**


46

47 Event#: 1 **Scan(E+)** Ret. Time: [0.560->1.760] - [0.000->0.560] Scan#: [57->177] - [1->57]




48

49 Event#: 2 **Scan(E+)** Ret. Time: [0.565->1.765] - [0.005->0.565] Scan#: [59->179] - [3->59]



50


51 Event#: 3 **Profile(E+)** Ret. Time: [0.601->1.801] - [0.041->0.601] Scan#: [63->183] - [7->63]



52

53


54 **(B) Contour View**



55

56 **Figure S3.** Electrospray ionization mass spectrometric (ESIMS) analysis of the Cy3-SBP1-
57 CONH₂ peptide. The lyophilized peptide was dissolved in 1:1 acetonitrile-water mixture
58 containing 0.1% trifluoroacetic acid and directly injected in the MS for the analysis. (A) Shows
59 the ESI-MS spectra of the peptide in the positive mode (in the spectrum view), Event#: (1)
60 from m/z = 0 to 1000, (2) m/z = 1000 to 2000 and (3) Profile mode: from m/z = 0 to 2000, with
61 the [M + 3H]³⁺, [M + 4H]⁴⁺ and [M + 5H]⁵⁺ peaks (highlighted in red) having the maximum
62 intensities. (B) Shows the elution profile in the contour view confirming the presence of the
63 Cy3-labelled peptide.


64



65

66 **Figure S4.** MALDI-TOF mass spectrum (in reflector positive mode) of the SBP1^{mod}-CONH₂ (H₂N-
67 SBP1^{mod}-CONH₂, modified SBP1) peptide. The peak at m/z = 2702.21 (highest intensity peak)
68 corresponds to SBP1^{mod}-CONH₂ peptide.

69



70

71 **Figure S5.** Normalized fluorescence autocorrelation data obtained from free rhodamine 110
 72 in solution (black, solid line), 140 nM Rh110-labelled SBP1^{mod} peptide after 30 minutes (green,
 73 dotted line) and 24 hours (violet, dashed line) of incubation.

74

75 Photon Counting Histogram (PCH) Analysis:


76

77 We have carried out a PCH analysis of the FCS data. The experimental PCH data is obtained
 78 using a MATLAB program from time trace measurement in Time Tagged Time-Resolved (TTTR)
 79 mode using PicoHarp 300 software (Picoquant). The PCH data is fitted with the following
 80 equation for multiple independent species¹ using a code written in Python.

81
$$\pi(k; \bar{N}_1, \bar{N}_2, \epsilon_1, \epsilon_2) = \pi(k; \bar{N}_1, \epsilon_1) * \pi(k; \bar{N}_2, \epsilon_2)$$

82 Where the function $\pi(k; \bar{N}, \epsilon)$ describes the probability of observing k photon counts in an
 83 open system for a single species particle solution with \bar{N}_1, \bar{N}_2 representing the average
 84 number of particles corresponding to species 1 and 2 respectively and ϵ_1, ϵ_2 representing
 85 brightness of molecule of species 1 and 2 respectively.

86 While a solution containing monomers and dimers [Fig. S6 (A)] does fit well. A solution
 87 containing only monomers do not fit well [Fig. S6 (B)]. PCH fits including larger number of
 88 components, given the quality of the data, does not provide unique parameter values.
 89 However, this analysis shows that the solution cannot have just monomers.



90


91 **Figure S6.** Photon counting histogram for SBP1^{mod} at 140 nM. (A)The histogram is fitted with
 92 2 species having different brightness (ϵ) values ($\epsilon_1 = 0.12, \epsilon_2 = 0.24$, for the monomer and the
 93 dimer) with 1:2.3 ratio for \bar{N}_1 and \bar{N}_2 respectively, using the theoretical PCH function $\pi(k;$
 94 $\bar{N}_1, \bar{N}_2, \epsilon_1, \epsilon_2)$ ¹.The inset displays the same data in linear scale for comparison. (B) The
 95 histogram is fitted with 1 species using the theoretical PCH function $\pi(k; \bar{N}, \epsilon)$ ¹ having $\epsilon = 0.20$
 96 and $\bar{N} = 95$. The inset displays the same data in linear scale for comparison.

97

98

99 Dynamic Light Scattering (DLS) for Monitoring Aggregation of SBP1 and SBP1^{mod}:
100


101 It is well-known that adding a fluorescence label can potentially alter the properties of any
102 peptide. We have now carried out DLS measurements of both SBP1 and SBP1^{mod} (unlabelled)
103 to clarify whether the observed oligomerization is an effect of the labelling or is somehow
104 altered upon dye labelling. Fig. S7 shows the correlation traces of SBP1 and SBP1^{mod} at 1 μ M
105 [Panels (A) and (B)] and at 10 μ M [Panels (C) and (D)], respectively] concentrations. We
106 observe multiple traces which show the presence of larger aggregates in the solution. We
107 cannot access concentration below this for such a small peptide, due to the lack of sensitivity
108 of DLS (compared to FCS). We conclude that while the fluorescent labels may change some
109 properties, the peptide has a tendency to aggregate even without any fluorescent labels.



110

111 **Figure S7.** Correlation curves obtained from the dynamic light scattering (DLS) measurements
112 of SBP1 and SBP1^{mod} at concentrations of 1 μ M [Panels (A) and (B)] and at 10 μ M [Panels (C)
113 and (D)], respectively.


114



115

116 **Figure S8.** (A) TIRF image of freshly prepared Cy3-labelled SBP1 (1 nM) on glass coverslip.
 117 Scale bar is 5 µm. (B) Time traces observed during the photobleaching of individual SBP1
 118 oligomers.

119



120

121 **Figure S9.** (A) TIRF image of Cy3-labelled SBP1 (1 nM) after 24 hours of incubation. Scale bar
 122 is 5 μm. (B) Time traces observed during the photobleaching of individual SBP1 oligomers.

123

124

125

126

127

128

129

130

131


132

133


134

135 Comparison of the extent of oligomerization of SBP1 and SBP1^{mod} from Single-
136 Molecule Photobleaching (smPB) Experiment:
137

138 We have checked the decrease in the Cy3-SBP1 peptide concentration as a result of sticking
139 to the wall of the tube by measuring the Cy3 fluorescence in the solution. We see that the
140 concentration of a 1 nM solution, after 24 hrs, decreases to 720 pM. We then measured the
141 stoichiometry of the oligomers of a freshly prepared solution having the same 720 pM
142 concentration. We also repeated the same experiments with Cy3-SBP1^{mod}. In this case, the
143 concentration reduces to 733 pM after 24 hrs.



144



145

146 **Figure S10.** Pre-bleach corrected oligomer distributions of (A) a fresh 1 nM solution of Cy3-
 147 SBP1 peptide, (C) after 24 hrs rotation with a final concentration 720 pM, (E) a fresh 720 pM
 148 peptide solution. Similarly, for Cy3-SBP1^{mod} (modified SBP1), (B) oligomeric distribution of a
 149 fresh 1 nM solution, (D) after 24 hrs rotation with a final concentration of 733 pM, (F) a fresh
 150 733 pM solution. For SBP1 fresh N = 485 points (3 sets), SBP1 after 24 hrs N = 373 points (3
 151 sets), SBP1 720 pM N = 428 points (3 sets), SBP1^{mod} fresh N = 392 points (3 sets), SBP1^{mod} after
 152 24 hrs N = 305 points (3 sets), SBP1^{mod} 733 pM N = 354 points (3 sets). For each sets 6 ROIs
 153 (region of interest) are taken. Average and standard error of the mean (plotted error) are
 154 calculated.

155

156

157 Figure S10 (A) represents the SBP1 pre-bleach corrected oligomeric distribution of a fresh 1
 158 nM stock. This, after 24 hrs, changes to a monomer heavy distribution [Figure S10 (C)]. The
 159 concentration in Figure S10 (C) is 720 pM. A fresh SBP1 stock of the same concentration
 160 [Figure S10 (E)], on the other hand, shows a very similar distribution as that in Figure S10 (A).
 161 This suggests that monomerization was not due to a mismatch in concentration. Data shown
 162 in Figure S10 (A) and S10 (C) are fresh repeats of those shown in Figure 4 (C) and 4 (D)
 163 respectively. We observe a slight variation in the relatively ratios of the population of different
 164 oligomers, however, the data does not change qualitatively.

165 A similar observation is seen in the case of Cy3-SBP1^{mod} also. Figure S10 (B) represents the
 166 oligomeric distribution of the fresh 1 nM stock of Cy3-SBP1^{mod}. The oligomerization status
 167 shows that it is less aggregation prone than SBP1. After 24 hrs, the oligomer changes to a
 168 monomer heavy distribution as shown in Figure S10 (D). The concentration was measured to
 169 be 733 pM. A fresh stock solution of the same concentration [Figure S10 (F)] showed a very
 170 similar oligomer distribution as in Figure S10 (B).

171 Hence, for both the systems, we see that the observed monomerization is a time dependent
 172 phenomenon, and is not caused by a mismatch in concentration between the samples.

173

174 Section S1: Theoretical calculations of hydrodynamic radius and comparison with
175 the experimental results

176

177 We have calculated the expected hydrodynamic radius of the SBP1 peptide given its length
178 (and aspect ratio) in the crystal structure. Detailed calculations are shown below:

179 The axial ratio or aspect ratio $p = (a/b)$, where $a =$ end to end distance (C-alpha, measured) =
180 3.3 nm and $b =$ diameter (including side chain, from ideal helix assumption) = 1.2 nm. Hence,
181 $p = 32.88/12 = 2.74$. For a prolate spheroid of this aspect ratio, the Perrin factor is $\sim 1.1^2$.

182 Hence the expected effective hydrodynamic radius, $R_h = \left(\frac{3V}{4\pi}\right)^{\frac{1}{3}} \times f_p \sim 1.06 \text{ nm}$

183

184 From our FCS measurements, we observe that SBP1 has a hydrodynamic radius of 3.1 ± 0.2
185 nm, and the SBP1^{mod} peptide has a radius of 2.6 ± 0.1 nm. Both of these values are larger than
186 that calculated for the helical monomer (above), so it suggests oligomerization. After 24 hours
187 of incubation, both the peptides have a very similar hydrodynamic radii of ~ 2.5 nm. If we
188 assume a quasi-spherical shape for the oligomer, then the initial aggregation state (average)
189 of SBP1 is ~ 25 -mers and that of SBP1^{mod} is ~ 15 -mers, while after 24 hours, the average
190 stoichiometry becomes ~ 13 -mers. This of course assumes that the peptide remains in the
191 helical state, which is not true. If the peptide is more disordered, the actual number of
192 monomers in an oligomer would be smaller, as we show below.

193

194 A random coil is likely to be smaller than the long helix, so formally it might be suggested that
195 the slow change in radius represents a loss of secondary structure by hydrophobic solvation
196 of the molecule. However, as we see below, it turns out not to be true.

197 For a Gaussian random coil peptide in a good solvent, an estimate for the hydrodynamic
198 radius (R_h) of random coil peptides is provided by Wilkins *et al.*³. For unfolded proteins, $R_h =$
199 $2.21 \times N^{0.57}$, which yields a value of 1.32 nm. Therefore, a random coil would actually have a
200 higher R_h than a compact cylinder (~ 1.06 nm, as shown before), as far as SBP1 is concerned.
201 Therefore, the slow reduction of the radius is unlikely to represent a loss of secondary
202 structure.

203 This supports our inference that the initial solutions as well as 24-hours incubated solutions
204 of both SBP1 and SBP1^{mod} (at 140 nM) contain oligomeric species. If we calculate on the basis
205 of the random coil radius (taken to be 1.32 nm), the average oligomer size of 2.5 nm
206 corresponds to about 7-mers. At lower concentration, the R_h for SBP1 initially becomes ~ 1.7
207 nm, which corresponds to dimers on an average, and after incubation, it becomes ~ 1.4 nm
208 (which corresponds to a nearly monomeric state) [Fig. 3B and 3D]. This is not far off from the
209 values measured in our single molecule photobleaching measurements, where we incubated
210 the SBP1 peptide at a concentration of 3 nM for 70 minutes.

211

212 Section S2: Computational methods

213

214 In order to examine the binding of the SBP1 in the helical as well as in the non-helical
215 (unwound) form, we docked the structure with the RBD of the S-protein. The helical
216 conformation of the peptide and RBD were both modelled using the crystal structure of ACE2
217 bound to the RBD, present in RCSB database with PDB ID: 6MOJ⁴ (Fig. 1A). For docking,
218 Haddock 2.4 (July 2020) with CNS 1.3 was used^{5,6}. The results were analyzed using in-house
219 scripts and visualizations were carried out using VMD⁷.

220

221 In order to define the binding interface for docking studies, the crystal structure of
222 RBD bound to ACE2 complex (PDB ID: 6MOJ⁴) was used to include all residues within 10Å of
223 the ACE2 N-terminal segment 21 to 44. All the residues were considered as 'active' residues
224 for docking purposes. In order to model the SBP1, we extracted residues 21 to 44 of ACE2
225 from the same complex (PDB ID: 6MOJ⁴) and mutated the 44th residue to lysine using
226 CHARMM-GUI⁸. The whole α -helical SBP1 peptide was considered to also be 'active' during
227 docking. The whole peptide was considered to be semi-flexible although strict conditions
228 were provided to preserve the secondary structure of SBP1 to be α -helical. In docking the
229 helical form of SBP1 with RBD, 6000 structures were initially selected for rigid body docking,
230 with the best 400 (based on binding energy scores) chosen for final full flexible refinement
231 and further analysis. All other docking options were set as per default values defined in
232 Haddock (see Table S1).

233

234 In order to carry out the docking studies with the 'unwound' form of SBP1, we
235 generated extended SBP1 conformations using a combination of MD simulations and
236 simulated annealing protocols. These computations were carried out using NAMD software
237 version 2.13⁹ and the CHARMM36 force field¹⁰ for the peptide. For modelling SBP1, the
238 coordinates of residue 21 to 44 were extracted from the crystal structure of RBD-ACE2
239 complex (PDB ID: 6MOJ) and the residue 44 was mutated to lysine using CHARMM-GUI. Then,
240 we heated the protein in vacuum from 0 to 700 K at a rate of 6K/ps and then evolved the
241 system for ~ 2 ns with a time step of 1 fs. After that the protein was cooled from 700 to 300
242 K at a rate of 6K/ps and then evolved again for ~ 2 ns. The cooling step was repeated 5 times
243 to generate different non-helical conformation of SBP1. The 5 non-helical structures of SBP1
244 thus obtained were solvated in a rectangular TIP3P water box with a solvent padding of 12 Å
245 around the protein and neutralized by adding 4 sodium ions. The Particle mesh Ewald (PME)
246 method for electrostatics with a cutoff value of 12 Å for long-range non-bonded interactions
247 was used. Langevin dynamics and the Nose-Hoover Langevin piston barostat method are used
248 to implement temperature and pressure control respectively. The solvated system was first
249 minimized for 1000 steps and then gradually heated to 300 K while keeping the protein non-
250 hydrogen atoms fixed. Finally, an unconstrained 1 ns NPT run was performed to equilibrate
251 the system at a pressure of 1 bar and temperature of 300 K. This is followed by 10 ns
252 production runs under NVT conditions with a time step of 2 fs. The structure of the peptides

253 obtained at the end of 5 independent NVT runs are taken as input SBP1 conformations for
 254 docking to RBD to check the binding energies. For docking of the non-helical (unwound) SBP1
 255 structures, the definition of the binding interface remained the same as given above for the
 256 helical conformation). However, in order to account for the greater flexibility of the non-
 257 helical conformation during the process of docking, 10000 structures were generated from
 258 rigid body docking, out of which the 1000 best (based on binding energy scores) structures
 259 were chosen for fully flexible optimizations and further analysis. In this case, the number of
 260 steps used during optimization including heating and dynamics stages were four times longer
 261 than the default values. In all cases, cluster analysis was performed using root mean square
 262 deviation (RMSD) based clustering with a cutoff of 5Å. A complete list of parameters which
 263 differ for docking helical and non-helical conformers along with Haddock defaults is given in
 264 Table S1. All other setting/parameters used were as per Haddock defaults.

265

Parameter	Default	Helix	Non-Helical
ssdihed	none	alphabet	none
structures_0	6000	6000	10000
structures_1	400	400	1000
anastruc_1	400	400	1000
waterrefine	400	400	1000
waterheatsteps	100	100	500
watersteps	1250	1250	5000
watercoolsteps	500	500	2000
clust_meth	FCC	RMSD	RMSD
clust_cutoff	0.6	5	5

266

267 **Table S1.** Docking options used in Haddock for docking of helical and non-helical states of
 268 SBP1 with RBD of S-protein. Haddock default values are provided as a reference.

269

270

271

272

273

274

275

276

277

278

279




Figure S11. (A) Comparison of the binding mode for the N-terminal segment 23-41 of ACE2 and the helical conformation of SBP1 with RBD (surface and secondary structure representation). (B) Binding energies for the 1000 best RBD docked structures of helical and non-helical SBP1 peptides. (C) Binding modes of the 5 non-helical SBP1 structures derived from MD and simulated annealing with RBD.

280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294

No	SBP1 Structure	Binding Energy Scores
1	Helix	-416.888 kcal mol ⁻¹
2	Non-helical 1	-346.787 kcal mol ⁻¹
3	Non-helical 2	-361.570 kcal mol ⁻¹
4	Non-helical 3	-311.241 kcal mol ⁻¹
5	Non-helical 4	-432.882 kcal mol ⁻¹
6	Non-helical 5	-309.539 kcal mol ⁻¹
7	Non-helical Average	-352.404 kcal mol ⁻¹

295

296 **Table S2.** Haddock binding energy scores of the best docking poses of SBP1 (helical and 5 non-
 297 helical conformations) with RBD of S-protein (PDB ID: 6M0J⁴).

298

299

300

301

302

303

304

305

SBP1(H):RBD		SBP1(NH1):RBD		SBP1(NH2):RBD		SBP1(NH3):RBD		SBP1(NH4):RBD		SBP1(NH5):RBD	
RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1
Y505	E37	Q493	K26	Y449	Q42	K417	E23	S494	Q42	Q493	T27
K417	D30	Y489	E22	R408	E23	G502	S43	Q493	S43	Y489	Y41
N487	I21	N487	E22	D405	K26	Q493	T27	N487	Q24	N487	Q42
N487	Q24	K417	E23			E484	K31	K417	E23	K417	E35
Q498	Q42							Q409	E37	N501	K31
E484	K31							K417	E37	K417	E35
S477	Q24							Y505	F32		
F497	Q42							E484	S43		

306

307

308 **Table S3.** H-bonding interactions of helical and non-helical SBP1 with the spike RBD. The table
 309 shows the residues of SBP1 and RBD which form H-bonds with each other in SBP1:RBD
 310 complexes.

311

SBP1(H):RBD		SBP1(NH1):RBD		SBP1(NH2):RBD		SBP1(NH3):RBD		SBP1(NH4):RBD		SBP1(NH5):RBD	
RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1	RBD	SBP1
K417	D30	K417	E23	D405	K26	E484	K31	K417	E23	K417	E35
E484	K31	D405	K44	R408	E23						
R403	E37										

312

313

314 **Table S4.** Salt-bridge interactions of helical and non-helical SBP1 with the spike RBD. The table
315 shows the residues of SBP1 and RBD which form salt-bridges with each other in SBP1:RBD
316 complexes.

317

318 SI References:

319

- 320 (1) Chen, Y.; Müller, J. D.; So, P. T. C.; Gratton, E. The Photon Counting Histogram in
321 Fluorescence Fluctuation Spectroscopy. *Biophys. J.* **1999**, *77* (1), 553–567.
322 [https://doi.org/https://doi.org/10.1016/S0006-3495\(99\)76912-2](https://doi.org/https://doi.org/10.1016/S0006-3495(99)76912-2).
- 323 (2) Cantor, C. R.; Schimmel, P. R. *Biophysical Chemistry: Part III: The Behavior of*
324 *Biological Macromolecules*; Biophysical chemistry; W. H. Freeman, 1980.
- 325 (3) Wilkins, D. K.; Grimshaw, S. B.; Receveur, V.; Dobson, C. M.; Jones, J. A.; Smith, L. J.
326 Hydrodynamic Radii of Native and Denatured Proteins Measured by Pulse Field
327 Gradient NMR Techniques. *Biochemistry* **1999**, *38* (50), 16424–16431.
328 <https://doi.org/10.1021/bi991765q>.
- 329 (4) Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.;
330 et al. Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2
331 Receptor. *Nature* **2020**, *581* (7807), 215–220. [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-2180-5)
332 [2180-5](https://doi.org/10.1038/s41586-020-2180-5).
- 333 (5) Dominguez, C.; Boelens, R.; Bonvin, A. M. J. J. HADDOCK: A Protein–Protein Docking
334 Approach Based on Biochemical or Biophysical Information. *J. Am. Chem. Soc.* **2003**,
335 *125* (7), 1731–1737. <https://doi.org/10.1021/ja026939x>.
- 336 (6) van Zundert, G. C. P.; Rodrigues, J. P. G. L. M.; Trellet, M.; Schmitz, C.; Kastiris, P. L.;
337 Karaca, E.; Melquiond, A. S. J.; van Dijk, M.; de Vries, S. J.; Bonvin, A. M. J. J. The
338 HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular
339 Complexes. *J. Mol. Biol.* **2016**, *428* (4), 720–725.
340 <https://doi.org/https://doi.org/10.1016/j.jmb.2015.09.014>.
- 341 (7) Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics. *J. Mol.*
342 *Graph.* **1996**, *14* (1), 33–38. [https://doi.org/10.1016/0263-7855\(96\)00018-5](https://doi.org/10.1016/0263-7855(96)00018-5).
- 343 (8) Jo, S.; Kim, T.; Iyer, V. G.; Im, W. CHARMM-GUI: A Web-Based Graphical User

- 344 Interface for CHARMM. *J. Comput. Chem.* **2008**, *29* (11), 1859–1865.
345 <https://doi.org/https://doi.org/10.1002/jcc.20945>.
- 346 (9) Phillips, J. C.; Hardy, D. J.; Maia, J. D. C.; Stone, J. E.; Ribeiro, J. V; Bernardi, R. C.; Buch,
347 R.; Fiorin, G.; Hénin, J.; Jiang, W.; et al. Scalable Molecular Dynamics on CPU and GPU
348 Architectures with NAMD. *J. Chem. Phys.* **2020**, *153* (4), 44130.
349 <https://doi.org/10.1063/5.0014475>.
- 350 (10) Huang, J.; MacKerell Jr, A. D. CHARMM36 All-Atom Additive Protein Force Field:
351 Validation Based on Comparison to NMR Data. *J. Comput. Chem.* **2013**, *34* (25), 2135–
352 2145. <https://doi.org/https://doi.org/10.1002/jcc.23354>.
- 353
- 354